Overview

Efficacity and Safety of Metformin XR in CKD Stage 1 to 3

Status:
Unknown status
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
There is limited data availability on effect of Metformin XR on 24-h plasma glucose, and there is no available data in chronic kidney disease (CKD). The planned study aims to provide data on glucose plasma level in relation to metformin plasma level in Diabetes Type II patients.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Treatments:
Metformin